Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells

Research in Veterinary Science

Volumn 97, Issue 1, 2014, Pages 60-63

  Fujiwara Igarashi, Aki ^a   Goto Koshino, Yuko ^a   Mochizuki, Hiroyuki ^a   Sato, Masahiko ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dog; Hypermethylation; Lymphoma; P16; Tumor suppressor gene

Indexed keywords

MESSENGER RNA; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PRIMER DNA;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOG; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENETIC REGULATION; LYMPHATIC SYSTEM TUMOR; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SEQUENCE ANALYSIS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; ANIMAL; DOG DISEASE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LYMPHOMA; MOLECULAR GENETICS; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA PRIMERS; DOG DISEASES; DOGS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, TUMOR SUPPRESSOR; LYMPHOMA; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC;

EID: 84905223282     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2014.04.008     Document Type: Article

References (23)

1. Bryan J.N., Jabbes M., Berent L.M., Arthur G.L., Taylor K.H., Rissetto K.C., et al. Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. BMC Genetics 2009, 10:73.
2. Cheung H.H., Lee T.L., Rennert O.M., Chan W.Y. DNA methylation of cancer genome. Birth Defects Research. Part C, Embryo Today: Reviews 2009, 87:335-350.
3. Claus R., Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003, 22:6489-6496.
4. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998, 12:845-859.
5. Ferraresso S., Bresolin S., Arico A., Comazzi S., Gelain M.E., Riondato F., et al. Epigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphoma. PLoS ONE 2014, 9:e92707.
6. Fosmire S.P., Thomas R., Jubala C.M., Wojcieszyn J.W., Valli V.E., Getzy D.M., et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Veterinary Pathology 2007, 44:467-478.
7. Fujiwara-Igarashi A., Goto-Koshino Y., Mochizuki H., Maeda S., Fujino Y., Ohno K., et al. Simultaneous inactivation of the p16, p15 and p14 genes encoding cyclin-dependent kinase inhibitors in canine T-lymphoid tumor cells. The Journal of Veterinary Medical Science 2013, 75:733-742.
8. Fujiwara-Igarashi A., Goto-Koshino Y., Sato M., Maeda S., Igarashi H., Takahashi M., et al. Prognostic significance of the expression levels of the p16, p15, and p14 genes in dogs with high-grade lymphoma. The Veterinary Journal 2014, 199:236-244.
9. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. Journal of Molecular Biology 1987, 196:261-282.
10. Gil J., Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nature Reviews. Molecular Cell Biology 2006, 7:667-677.
11. Haluskova J. Epigenetic studies in human diseases. Folia Biologica (Praha) 2010, 56:83-96.
12. Holliday R. DNA methylation and epigenetic defects in carcinogenesis. Mutation Research 1987, 181:215-217.
13. Holliday R. Epigenetics: A historical overview. Epigenetics 2006, 1:76-80.
14. Krimpenfort P., Quon K.C., Mooi W.J., Loonstra A., Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001, 413:83-86.
15. Krug U., Ganser A., Koeffler H.P. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002, 21:3475-3495.
16. Momoi Y., Okai Y., Watari T., Goitsuka R., Tsujimoto H., Hasegawa A. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Veterinary Immunology and Immunopathology 1997, 59:11-20.
17. Nakaichi M., Taura Y., Kanki M., Mamba K., Momoi Y., Tsujimoto H., et al. Establishment and characterization of a new canine B-cell leukemia cell line. The Journal of Veterinary Medical Science 1996, 58:469-471.
18. Russo A.A., Tong L., Lee J.O., Jeffrey P.D., Pavletich N.P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998, 395:237-243.
19. Rutgen B.C., Hammer S.E., Gerner W., Christian M., de Arespacochaga A.G., Willmann M., et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leukemia Research 2010, 34:932-938.
20. Santos-Reboucas C.B., Pimentel M.M. Implication of abnormal epigenetic patterns for human diseases. European Journal of Human Genetics 2007, 15:10-17.
21. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
22. Stein R.A. Epigenetics and environmental exposures. Journal of Epidemiology & Community Health 2012, 66:8-13.
23. Yamazaki J., Baba K., Goto-Koshino Y., Setoguchi-Mukai A., Fujino Y., Ohno K., et al. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Veterinary Immunology and Immunopathology 2008, 126:321-331.